19. Dyskinesias in Parkinsonian Syndromes

  1. Alberto Albanese MD3 and
  2. Joseph Jankovic MD4
  1. S. Elizabeth Zauber1 and
  2. Christopher G. Goetz2

Published Online: 24 FEB 2012

DOI: 10.1002/9781444346183.ch19

Hyperkinetic Movement Disorders: Differential Diagnosis and Treatment

Hyperkinetic Movement Disorders: Differential Diagnosis and Treatment

How to Cite

Zauber, S. E. and Goetz, C. G. (2011) Dyskinesias in Parkinsonian Syndromes, in Hyperkinetic Movement Disorders: Differential Diagnosis and Treatment (eds A. Albanese and J. Jankovic), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444346183.ch19

Editor Information

  1. 3

    Fondazione IRCCS Istituto Neurologico Carlo Besta, Università Cattolica del Sacro Cuore, Milan, Italy

  2. 4

    Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX, USA

Author Information

  1. 1

    Department of Neurology, Indiana University School Medicine, Indianapolis, IN, USA

  2. 2

    The Parkinson Disease and Movement Disorder Center, Rush University Medical Center, Chicago, IL, USA

Publication History

  1. Published Online: 24 FEB 2012
  2. Published Print: 3 APR 2011

ISBN Information

Print ISBN: 9781444333527

Online ISBN: 9781444346183



  • levodopa-induced-dyskinesia;
  • diphasic dyskinesia;
  • progressive supranuclear palsy;
  • corticobasal degeneration;
  • multiple system atrophy;
  • Parkinson's disease;
  • deep brain stimulation;
  • pathophysiology


Dyskinesia is an involuntary hyperkinetic movement disorder that may occur as a feature of parkinsonism or as an effect of drug treatment for the disease. In Parkinson's disease (PD) dyskinesia is common and may be disabling. The phenomenology of dyskinesia in PD varies primarily due to the level of brain dopamine from dopaminergic drugs in the context of dopaminergic cell degeneration. While changes in the dopaminergic system are essential for the development of dyskinesia, multiple other brain receptor systems are implicated in the pathophysiology. Currently only one drug, amantadine, reduces dyskinesia severity without worsening parkinsonism. Other treatment options consist of changes in dose and timing of dopaminergic drugs, as well as deep brain stimulation surgery.